29 results
8-K
EX-3.1
ATRX
Adhera Therapeutics, Inc.
6 Oct 22
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
EX-3.1
ATRX
Adhera Therapeutics, Inc.
9 Oct 18
Marina Biotech Announces Name Change to Adhera Therapeutics to More Closely Reflect the Mission of Improving Patient Outcomes
8:30am
8-K
EX-3.1
ATRX
Adhera Therapeutics, Inc.
16 Jul 18
Entry into a Material Definitive Agreement
9:02am
8-K
EX-3.1
ATRX
Adhera Therapeutics, Inc.
19 Apr 18
Entry into a Material Definitive Agreement
12:00am
8-K
EX-3.1
ATRX
Adhera Therapeutics, Inc.
2 Aug 17
Marina Biotech Announces 1-for-10 Reverse Stock Split in Preparation for Proposed Up-Listing of its Common Stock to the NASDAQ Capital Market
12:00am
8-K
EX-3.1
ojy7vzcq
10 Aug 15
Marina Biotech’s CEQ508 Granted FDA Fast Track Designation
12:00am
8-K
EX-3.1
lmlzhsw 52y1ntyjr6s
11 Mar 14
Marina Biotech to use its RNAi, Antisense and microRNA Therapeutics Platform to Develop Drugs for Rare Diseases
12:00am
8-K
EX-3.2
ap1769bov tf
23 Dec 11
Marina Biotech Announces $5 Million Private Placement
12:00am
8-K
EX-3.1
gtgqhrezo
23 Dec 11
Marina Biotech Announces $5 Million Private Placement
12:00am
8-K
EX-3.1
cen5npxdj
18 Jul 11
Marina Biotech Announces Changes to Board of Directors
12:00am
8-K
EX-3.1
y8z863a bn
23 Jul 10
MDRNA, Inc. Shareholders Approve Acquisition of Cequent Pharmaceuticals
12:00am
8-K
EX-3.1
rjoywvf
21 Jul 10
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
EX-3.1
lvnt9 le0
13 Jun 08
Nastech Initiates New Corporate Direction with Name Change to MDRNA, Inc. and Appointment of J. Michael French as Chief Executive Officer
12:00am
8-K
EX-3.2
c6bmdoo0k6
13 Jun 08
Nastech Initiates New Corporate Direction with Name Change to MDRNA, Inc. and Appointment of J. Michael French as Chief Executive Officer
12:00am
8-K
EX-3.1
t1ogi
25 Sep 07
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
EX-3.1
mnc3uv
19 Jan 07
Entry into a Material Definitive Agreement
12:00am
8-K
EX-3.1
yfls3t
25 Jul 05
Entry into a Material Definitive Agreement
12:00am